Danaher's Tax Line Swung To A $75 Million Benefit As Diagnostics Margin Fell To 21.3%

Released tax reserves drove third-quarter earnings per share to $1.71, while Diagnostics margin dropped after the Masimo deal.

Share
Danaher's Tax Line Swung To A $75 Million Benefit As Diagnostics Margin Fell To 21.3%

Danaher booked a $75 million income-tax benefit in the third quarter, against $168 million of tax expense a year earlier, after net discrete tax benefits of $263 million from released reserves pushed the effective tax rate to negative 6.6%, according to the company's 10-Q. Those settled audits, more than operations, explain the jump in earnings from continuing operations, while margins in the newly enlarged Diagnostics segment fell.

The tax release behind the earnings jump

Earnings per diluted share from continuing operations were $1.71, up from $1.27. The 10-Q says the $0.37 per share tax benefit, from reserves for uncertain tax positions released after audit settlements, and 2025 impairment charges drove the year-over-year increase.

Company-wide operating profit margin slipped to 19.0% from 19.1%. Adjusted earnings per share, the company's own measure, rose 11.5% to $2.11, according to the earnings release, which put revenue at $6.6 billion, up 8.5%.

Discontinued operations also carried a $28 million benefit from settled audits of earlier joint filings with Veralto and Fortive.

Diagnostics: bigger, but thinner

Diagnostics sales rose 17.0%, primarily from the Masimo deal, but operating profit fell to $614 million from $665 million. Margin was 21.3%, against 27.0% a year earlier; the prior quarter's filing showed 16.9%.

The 10-Q lists the drags: acquired businesses' dilution cost 365 basis points (3.65 percentage points) and the Masimo inventory fair-value step-up cost 295, a charge of $84 million in the quarter. Core sales in the segment grew 0.5%, or 7.0% excluding respiratory testing.

Company-wide core sales rose 3.0%, or 5.5% excluding respiratory testing.

A changed yardstick for core sales

Beginning with this report, core sales exclude tariff refunds passed on to customers, a change the company said last quarter it intended to make. Those refunds reduced reported sales by 1.0% in the quarter. The 10-Q says the boost to net earnings from the refunds, after customer payouts, was less than $100 million.

Masimo was bought on June 10 for about $9.8 billion in cash and financed partly with long-term debt and commercial paper. A Life Sciences acquisition added $37 million in upfront cash and $79 million deferred.

Outlook

Danaher raised full-year adjusted earnings per share guidance to $8.57 to $8.62, from $8.45 to $8.60. It expects fourth-quarter core revenue excluding respiratory to rise 4.0% to 5.0%, with respiratory a headwind of about 150 basis points. It expects an effective tax rate of about 17.0% for the year, and the filing flags a $185 million charge on canceled special equity awards in the fourth quarter.

The company's quarterly dividend of $0.40 per share is payable October 30, 2026 to holders of record on September 30.

Sources

More on Danaher

All Danaher (DHR) coverage →